open access

Vol 25, No 5 (2020)
Reviews
Published online: 2020-09-01
Submitted: 2019-11-05
Get Citation

cfRNAs as biomarkers in oncology – still experimental or applied tool for personalized medicine already?

Tomasz Kolenda, Kacper Guglas, Dawid Baranowski, Joanna Sobocińska, Magda Kopczyńska, Anna Teresiak, Renata Bliźniak, Katarzyna Lamperska
DOI: 10.1016/j.rpor.2020.07.007
·
Rep Pract Oncol Radiother 2020;25(5):783-792.

open access

Vol 25, No 5 (2020)
Reviews
Published online: 2020-09-01
Submitted: 2019-11-05

Abstract

Currently, the challenges of contemporary oncology are focused mainly on the development of personalized medicine and precise treatment, which could be achieved through the use of molecular biomarkers. One of the biological molecules with great potential are circulating free RNAs (cfRNAs) which are present in various types of body fluids, such as blood, serum, plasma, and saliva. Also, different types of cfRNA particles can be distinguished depending on their length and function: microRNA (miRNA), PIWI-interacting RNA (piRNA), tRNA-derived RNA fragments (tRFs), circular RNA (circRNA), long non-coding RNA (lncRNA), and messenger RNA (mRNA). Moreover, cfRNAs occur in various forms: as a free molecule alone, in membrane vesicles, such as exosomes, or in complexes with proteins and lipids. One of the modern approaches for monitoring patient's condition is a "liquid biopsy" that provides a non-invasive and easily available source of circulating RNAs. Both the presence of specific cfRNA types as well as their concentration are dependent on many factors including cancer type or even reaction to treatment. Despite the possibility of using circulating free RNAs as biomarkers, there is still a lack of validated diagnostic panels, defined protocols for sampling, storing as well as detection methods.

In this work we examine different types of cfRNAs, evaluate them as possible biomarkers, and analyze methods of their detection. We believe that further research on cfRNA and defining diagnostic panels could lead to better and faster cancer identification and improve treatment monitoring.

Abstract

Currently, the challenges of contemporary oncology are focused mainly on the development of personalized medicine and precise treatment, which could be achieved through the use of molecular biomarkers. One of the biological molecules with great potential are circulating free RNAs (cfRNAs) which are present in various types of body fluids, such as blood, serum, plasma, and saliva. Also, different types of cfRNA particles can be distinguished depending on their length and function: microRNA (miRNA), PIWI-interacting RNA (piRNA), tRNA-derived RNA fragments (tRFs), circular RNA (circRNA), long non-coding RNA (lncRNA), and messenger RNA (mRNA). Moreover, cfRNAs occur in various forms: as a free molecule alone, in membrane vesicles, such as exosomes, or in complexes with proteins and lipids. One of the modern approaches for monitoring patient's condition is a "liquid biopsy" that provides a non-invasive and easily available source of circulating RNAs. Both the presence of specific cfRNA types as well as their concentration are dependent on many factors including cancer type or even reaction to treatment. Despite the possibility of using circulating free RNAs as biomarkers, there is still a lack of validated diagnostic panels, defined protocols for sampling, storing as well as detection methods.

In this work we examine different types of cfRNAs, evaluate them as possible biomarkers, and analyze methods of their detection. We believe that further research on cfRNA and defining diagnostic panels could lead to better and faster cancer identification and improve treatment monitoring.

Get Citation

Keywords

Liquid biopsy; Cancer; Molecular diagnostics; Personalized medicine; Circulating RNA

About this article
Title

cfRNAs as biomarkers in oncology – still experimental or applied tool for personalized medicine already?

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 5 (2020)

Pages

783-792

Published online

2020-09-01

DOI

10.1016/j.rpor.2020.07.007

Bibliographic record

Rep Pract Oncol Radiother 2020;25(5):783-792.

Keywords

Liquid biopsy
Cancer
Molecular diagnostics
Personalized medicine
Circulating RNA

Authors

Tomasz Kolenda
Kacper Guglas
Dawid Baranowski
Joanna Sobocińska
Magda Kopczyńska
Anna Teresiak
Renata Bliźniak
Katarzyna Lamperska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl